This edition of FT TOE covers technological developments and commercial implications of various neuromodulation therapies that are redefining the standard of care offered by traditional drug-based therapies. The issue covers a snapshot of the global neuromodulation industry, highlighting the intensity of research and commercial prospects for newer clinical applications of these therapies. Detailed analysis of the market and technological drivers and challenges are covered, along with their influence on value of care offered to patients. The issue covers four innovation portfolios within this technology sector, including information and analyst insights on potential business models that could redefine healthcare.
The Future Tech TechVision Opportunity Engine (TOE) captures emerging innovations in research and development, or profile existing technologies which have seen a resurgence in terms of new markets and applications. It usually provides a technology overview, drivers, challenges, research and development, analyst insights and key patent information. In some cases, technology convergence scenarios and future growth opportunities are outlined. It covers innovations and technologies in a variety of industry spaces including manufacturing, sensors, electronics, information and communications technologies, networks, lighting technologies, healthcare, medical devices, materials and coatings, and developments in the energy sector that contribute toward a sustainable and greener world.
The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: Neuromodulation therapies, deep brain stimulation, spinal cord stimulation, depression therapies